Fatigue assessment in Egyptian patients with hepatitis C virus-related chronic liver disease: Single center study

Table 3 Factors associated with significant fatigue among chronic hepatitis C patients, n (%)

Variables	Non-fatigue group (n = 218)	Significant fatigue group (n = 82)	P value
Age groups			0.081
< 45 years	49 (74.2)	17 (25.8)
45-59 years	87 (79.1)	23 (20.9)
≥ 60 years	82 (66.1)	42 (33.9)
Gender			0.274
Male	134 (70.5)	56 (29.5)
Female	84 (76.4)	26 (23.6)
Marital status			0.347
Single1	28 (66.7)	14 (33.3)
Married	190 (73.6)	68 (26.4)
Residence			0.039
Rural	130 (77.4)	38 (22.6)
Urban	88 (66.7)	44 (33.3)
Smoking			0.543
No	174 (71.9)	68 (28.1)
Yes	44 (75.9)	14 (24.1)
Co-morbidities (DM and/HTN)			0.195
No	114 (76.0)	36 (24.0)
Yes	104 (69.3)	46 (30.7)
Clinical stage			0.001
Chronic liver disease	43 (82.7)	9 (17.3)
Compensated liver disease	136 (78.2)	38 (21.8)
Decompensated liver disease	39 (52.7)	35 (47.3)
Child score (n = 248)			0.015
A	136 (80.0)	34 (20.0)
B	20 (71.4)	8 (28.6)
C	30 (60.0)	20 (40.0)
FIB-4 fibrosis classes			0.001
Low risk (FIB-4 < 1.45)	146 (80.7)	35 (19.3)
Intermediate risk (FIB from 1.45-3.25)	52 (28.8)	21 (28.8)
High risk (FIB-4 > 3.25)	20 (43.5)	26 (56.5)
MELD score			0.001
< 15	211 (78.1)	59 (21.9)
≥ 15	7 (23.3)	23 (76.7)
Ascites			0.001
No	173 (78.3)	48 (21.7)
Yes	45 (57.0)	34 (43.0)
History of GIT bleeding			0.026
No	184 (75.4)	60 (24.6)
Yes	34 (60.7)	22 (39.3)
History of hepatic encephalopathy			0.001
No	195 (78.3)	54 (21.7)
Yes	23 (45.1)	28 (54.9)
Antiviral treatment			0.003
No	20 (52.6)	18 (47.4)
Yes	198 (75.6)	64 (24.4)
The duration of last dose of antiviral treatment (n = 262)			0.033
< 1 year	2 (33.3)	4 (66.7)
≥ 1 year	196 (76.6)	60 (23.4)
Antiviral treatment response (n = 262)			0.059
Response	190 (76.9)	57 (23.1)
Failure	8 (53.3)	7 (46.7)
HCV infection duration2			0.001
< 10 years	138 (86.8)	21 (13.2)
≥ 10 years	80 (56.7)	61 (43.3)

¹Single includes individuals who are not currently married (single, divorced, widow).

²Hepatitis C virus infection duration categorized according to the median (< 10 years and ≥ 10 years).

DM: Diabetes mellitus; FIB-4: Fibrosis-4; HTN: Hypertension; HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; GIT bleeding: Gastrointestinal tract bleeding.